In the early 1980s a mysterious immune-collapse disease, AIDS, alarmed the world. At the Pasteur Institute, Barré-Sinoussi and Montagnier cultured patients’ lymph-node cells and, guided by increased reverse-transcriptase activity, isolated a new retrovirus. They called it LAV, later named human immunodeficiency virus (HIV). HIV uses the CD4 molecule to infect helper T cells and destroys them, causing immune deficiency. Soon after discovery, blood tests and mother-to-child prevention measures improved transfusion and transplant safety. Drugs targeting the viral reverse transcriptase and protease transformed AIDS from a death sentence into a manageable chronic illness. Yet vaccine development and drug resistance remain major challenges. Their basic virology breakthrough is a classic example of research directly benefiting global public health.

HIV belongs to the lentivirus subfamily of retroviruses and integrates into the host genome via a double-stranded DNA intermediate. The 1983 LAV/HIV-1 isolate showed a conical core and a p24Gag antigen distinct from HTLV, inducing cell fusion and death. Scientists confirmed the virus by Mg²⁺-dependent reverse-transcriptase assays, gradient density of 1.16 g/cm³, and electron microscopy. Molecular cloning revealed a 9.7 kb genome encoding 9 genes and 15 proteins; beyond gag-pol-env, accessory genes vif, vpr, tat, rev, vpu, and nef were identified. Tat and Rev regulate transcription and RNA export, whereas Nef supports immune evasion and viral replication. HIV uses CCR5 or CXCR4 as co-receptors, and gp120 variability helps it escape host antibodies. Phylogenetics traces its human origin to chimpanzee SIVcpz in Central Africa, likely crossing into humans in the early 1900s. Major transmission routes are sexual contact, blood exposure, and mother-to-child, with high viral loads during acute and untreated phases driving spread. Highly active antiretroviral therapy (HAART), introduced in 1996, combines reverse-transcriptase and protease inhibitors to suppress replication long-term. New integrase inhibitors and CCR5 antagonists enable once-daily regimens. Yet latent reservoirs and immense diversity hinder a cure, prompting research into shock-and-kill and gene-editing strategies. HIV studies have enriched virology, immunology, and drug-development knowledge and serve as a model for pandemic response.

Early sequencing of LAV revealed multiple splice acceptors in non-coding regions, predicting a complex mRNA landscape. The TAR element and Sp1 sites in the LTR underpin Tat-dependent transcriptional activation, later linked to the Tat-Cyclin T1-P-TEFb complex. The co-culture method developed by Barré-Sinoussi et al. allowed real-time observation of CD4 T-cell depletion while quantifying RT activity; subsequent PCR assays could measure <10 RNA copies mL⁻¹ and became clinical trial endpoints. High env variability and a glycan shield facilitate neutralization escape, driving broadly neutralizing antibody (bnAb) research. A gp41-mimetic peptide, enfuvirtide, became the first licensed fusion inhibitor. Loss of gut-associated Th17 cells promotes microbial translocation and chronic inflammation in untreated HIV. CRISPR/Cas9 multiplex guide strategies achieve proviral excision in vivo, curbing rebound and hinting at curative approaches. Single-cell RNA-seq uncovers transcriptional and chromatin states of latent cells, aiding reservoir-targeted drug discovery. These findings at the intersection of virology, immunology, and genome engineering are shaping new therapeutic paradigms.